Tradestie Institutional Equity Comparison Engine

PFE vs MRNA โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

PFE Overall Edge

PFE Captures Institutional Edge (3โ€“1 Pillars ยท 7โ€“3 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Pfizer Inc. (PFE) driven by superior Valuation, Growth & Margin, Options & Structure while MRNA counters with relative strength in Momentum & Technical. Fundamentally, PFE trades at 9.3x Forward P/E with 29.1% operating margin (-0.4% YoY revenue) versus MRNA at 23.0x Forward P/E and -80.8% operating margin (+29.2% YoY). In options structure, PFE sits in CONSOLIDATION (58th %ile IV; Dealer Gamma Walls on Pro) against MRNA sits in CONSOLIDATION (52nd %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner PFE
PFE 9.3x vs MRNA 23.0x Fwd P/E
Growth & Margin Winner PFE
Op Margin 29.1% vs -80.8% ยท YoY -0.4% vs +29.2%
Momentum & Technical Winner MRNA
1Y +10.1% vs +706.5% ยท 52W Pos 48% vs 67%
Options & Structure Winner PFE
CONSOLIDATION (58th %ile IV) vs CONSOLIDATION (52nd %ile IV)
PFE NYSE
Pfizer Inc.
Pharmaceutical Preparations
$27.40
-0.51% 1D
Market Cap $157.0B
1M Return -9.93%
1Y Return +10.13%
Forward P/E 9.3x
Unified AI Score
49.4 / 100 HOLD
Tech 30.0 Fund 51.0 Flow 68.0 Mom 60.0
MRNA NASDAQ
Moderna, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$195.00
-2.17% 1D
Market Cap $80.7B
1M Return -3.77%
1Y Return +706.45%
Forward P/E 23.0x
Unified AI Score
40.3 / 100 SELL
Tech 18.0 Fund 42.0 Flow 67.0 Mom 46.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: PFE +10.13% MRNA +706.45% Spread: +696.32 pp (MRNA Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period PFE Revenue MRNA Revenue PFE Op. Margin MRNA Op. Margin Margin Edge
FY2018 $40.8B $140M 27.3% -306.0% PFE
FY2019 $40.9B $60M 39.2% -906.8% PFE
FY2020 $41.6B $800M 22.0% -95.0% PFE
FY2021 $73.6B $18.5B 29.8% 72.0% MRNA
FY2022 $91.8B $19.3B 34.2% 48.9% MRNA
FY2023 $50.9B $6.85B 4.2% -61.9% PFE
FY2024 $63.6B $3.24B 12.6% -121.9% PFE
FY2025 $62.6B $1.94B 12.4% -158.1% PFE

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: PFE (7) vs MRNA (3)
Institutional Metric PFE MRNA Criterion Row Winner
Market Capitalization Scale $157.0B $80.7B Larger Scale PFE
Trailing P/E Ratio Valuation 39.3x 23.0x Lower Multiple MRNA
Forward P/E Ratio Valuation 9.3x 23.0x Lower Multiple PFE
Revenue Growth (YoY) Growth -0.4% +29.2% Higher Growth MRNA
Operating Margin (TTM) Profitability 29.1% -80.8% Higher Margin PFE
Net Profit Margin Profitability 6.3% -110.5% Higher Margin PFE
Return on Equity (ROE) Capital Efficiency 4.5% -34.5% Higher ROE PFE
52-Week Range Position Momentum 48% ($24โ€“$31) 67% ($22โ€“$281) Stronger Trend MRNA
Beta / 30D Volatility Risk Regime 0.18ฮฒ ยท 22% Vol 2.23ฮฒ ยท 78% Vol Lower Realized Risk PFE
Unified Institutional Score Composite Signal 49.4 / 100 (HOLD) 40.3 / 100 (SELL) Higher Composite PFE

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full PFE vs MRNA Buy Guide
PFE CONSOLIDATION
56d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 58th %ile
IV Regime Balanced (25thโ€“60th %ile)
Live PFE Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
MRNA CONSOLIDATION
22d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 52nd %ile
IV Regime Balanced (25thโ€“60th %ile)
Live MRNA Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither PFE nor MRNA registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.